Table 4.
Week 12 outcome measures in subjects with chronic and/or recurrent MDD with and without concurrent substance use disorder
| Measure | Substance Use Disorder |
Analyses |
||||
|---|---|---|---|---|---|---|
| Present N=87 (13.1%) |
Absent N=577 (86.9%) |
Unadjusted | Adjusteda | |||
| n (%) | n (%) |
OR (95%CI) |
p-value |
OR (95%CI) |
p-value | |
| Remission (last 2 consecutive QIDS-SR16 <6 and <8) | 25 (28.7) | 230 (39.9) | 0.69 (0.41,1.18) |
0.1756 | 0.70 (0.4,1.19) |
0.1782 |
| Last QIDS-SR16 <6 | 24 (27.6) | 215 (37.6) | 0.65 (0.38,1.11) |
0.1130 | 0.61 (0.35,1.07) |
0.0834 |
| Response (≥50% reduction QIDS-SR 16) | 41 (47.7) | 292 (52.5) | 0.95 (0.58,1.55) |
0.8235 | 1.004 (0.6,1.67) |
0.9874 |
| Exited acute phase | 31 (35.6) | 154 (26.7) | 1.7 (1.01,2.85) |
0.0456 | 1.64 (0.96,2.81) |
0.0689 |
| Last WSAS | 1.31 (0.84,2.01) |
0.2365 | 1.35 (0.85,2.13) |
0.2056 | ||
| 0 | 15 (18.1) | 91 (16.7) | ||||
| 1–10 | 14 (16.9) | 157 (28.9) | ||||
| 11–20 | 21 (25.3) | 121 (22.2) | ||||
| 21–30 | 15 (18.1) | 105 (19.3) | ||||
| –40 | 18 (21.7) | 70 (12.9) | ||||
| Mean (SD) | Mean (SD) | β | β | |||
| Maximum SAFTEE N worsenings | 10.2 (7.4) | 9.4 (6.1) | 0.996 | 0.9551 | 0.998 | 0.9757 |
| Last SAFTEE N worsenings | 5.9 (5.8) | 50 (4.9) | 0.143 | 0.2401 | 0.2033 | |
| Last QIDS-SR16 | 9.3 (5.5) | 8.0 (5.4) | 0.914 | 0.1788 | 0.890 | 0.1961 |
| Percent QIDS-SR16 change | −41 (32.5) | −47 (34.5) | 3.721 | 0.3894 | 2.388 | 0.5885 |
| IDS-C30 anxiety subscale | 2.9 (2.0) | 2.6 (2.1) | 0.092 | 0.3944 | 0.098 | 0.3683 |
| Last QOLI | −0.20 (2.59) | 0.23 (2.28) | −0.222 | 0.4631 | −0.178 | 0.5670 |
a
Adjusted for treatment, gender, PDSQ Hypochondriasis, insomnia.
Abbreviations: QIDS-SR16 = 16-item quick inventory of depressive symptomatology - self-rated, WSAS = work and social adjustment scale, SAFTEE = systematic assessment for treatment-emergent events, QOLI = quality of life inventory, PDSQ = psychiatric diagnostic screening questionnaire.